|Mr. John Michael Maslowski||Pres, CEO, PFO, Principal Accounting Officer & Director||337.4k||N/A||42|
|Mr. Robert G. Partridge||VP of Global Marketing, Communications and Investor Relations||N/A||N/A||N/A|
|Ms. Elizabeth A. Browning||Exec. VP of Marketing||N/A||N/A||N/A|
|Ms. Michele Mchugh-Mazzatta||VP of Sales||N/A||N/A||N/A|
|Dr. Pierre Compte||Managing Director of Switzerland||N/A||N/A||N/A|
Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company's gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.
Fibrocell Science, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 5; Compensation: 9.